JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Compugen Ltd

Fermé

1.52 -0.65

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.5

Max

1.52

Chiffres clés

By Trading Economics

Revenu

-1.1M

-7.2M

Ventes

813K

2.3M

P/E

Moyenne du Secteur

60.333

38.156

Marge bénéficiaire

-314.405

Employés

74

EBITDA

-912K

-8.4M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+357.52% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-545M

141M

Ouverture précédente

2.17

Clôture précédente

1.52

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Compugen Ltd Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 juil. 2025, 17:53 UTC

Principaux Mouvements du Marché

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 juil. 2025, 15:58 UTC

Résultats
Principaux Mouvements du Marché

Aon Shares Rise After 2Q Earnings Beat

25 juil. 2025, 15:08 UTC

Principaux Mouvements du Marché

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 juil. 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 juil. 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 juil. 2025, 20:40 UTC

Résultats

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 juil. 2025, 20:10 UTC

Résultats

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 19:56 UTC

Résultats

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 juil. 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 juil. 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 juil. 2025, 19:01 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 juil. 2025, 17:38 UTC

Principaux Mouvements du Marché

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 juil. 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25 juil. 2025, 17:13 UTC

Résultats

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 juil. 2025, 16:46 UTC

Résultats

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 juil. 2025, 16:45 UTC

Résultats

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 juil. 2025, 16:27 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 juil. 2025, 16:02 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 juil. 2025, 15:34 UTC

Résultats

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 juil. 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 juil. 2025, 15:05 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 juil. 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 juil. 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 juil. 2025, 14:36 UTC

Market Talk
Résultats

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Comparaison

Variation de prix

Compugen Ltd prévision

Objectif de Prix

By TipRanks

357.52% hausse

Prévisions sur 12 Mois

Moyen 7 USD  357.52%

Haut 10 USD

Bas 4 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

1.25 / 1.48Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.